JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1150
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Chris Schott maintains an Overweight rating on Regeneron Pharmaceuticals but lowers the price target from $1200 to $1150.
October 24, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Chris Schott maintains an Overweight rating on Regeneron Pharmaceuticals but lowers the price target from $1200 to $1150.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal may result in a neutral short-term impact on REGN's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100